Expeditors International of Wshngtn Inc (EXPD) Stock Price Today
Aura AI Summary
Key Stats
- $25.18BMarket Cap
- 1,003,557Volume
- IndustrialsSector
- $194.1252W High
- $113.1352W Low
- 43 DaysTypical Hold Time
- $24.72BEnterprise Value
- 0.84%Div Yield
- 100% Sell | 0% BuyTrading Activity
Track Expeditors International of Wshngtn Inc (EXPD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Expeditors International of Wshngtn Inc has traded between a low of $113.13 and a high of $194.12, highlighting its annual price range. Buy and sell Expeditors International of Wshngtn Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Most Recent News
ZenaTech launches AI-powered smart safety glasses Stacklens for field technicians, with pilots in 2027.
ZenaTech introduced Stacklens™, AI-powered smart safety glasses designed for field technicians and industrial workers, integrating hands-free AI assistance, real-time video support, and thermal imaging. The glasses aim to improve efficiency by allowi...

Class action lawsuit filed over Compass-Anywhere merger alleging regulatory misrepresentation.
The Rosen Law Firm has filed a class action lawsuit on behalf of former Anywhere Real Estate shareholders who received Compass, Inc. stock in a January 2026 merger. The suit alleges that Compass and its executives misrepresented their efforts to secu...

New data supports Furoscix ReadyFlow autoinjector for outpatient edema management in heart failure and CKD.
MannKind presented new clinical data at HFSA 2026 showing that Furoscix ReadyFlow, an autoinjector delivering subcutaneous furosemide, provides diuretic effects comparable to IV administration for treating edema in heart failure and chronic kidney di...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.